The Library
Induction concurrent chemoradiotherapy using paclitaxel and carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer - Asian experience
Tools
Yap, S. P., Lim, W. T., Foo, K. F., Hee, Siew Wan, Leong, S. S., Fong, K. W., Eng, P., Hsu, A. A. L., Wee, J. T. S., Agasthian, T., Koong, H. N. and Tan, E. H. (2008) Induction concurrent chemoradiotherapy using paclitaxel and carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer - Asian experience. Annals of the Academy of Medicine Singapore , 37 (5). pp. 377-382. ISSN 0304-4602 .
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://www.ncbi.nlm.nih.gov/pubmed/18536823
Abstract
INTRODUCTION:
It has been established that combined chemoradiotherapy treatment benefits selected patients with stage III Non Small Cell Lung Cancer (NSCLC). However, locoregional recurrence still poses a problem. The addition of surgery as the third modality may provide a possible solution. We report our experience of using the triple-modality approach in this group of patients.
MATERIALS AND METHODS:
This is a retrospective review of 33 patients with stage III NSCLC treated between 1997 and 2005. Patients have good performance status and no significant weight loss. There were 26 males (79 %) with median age of 63 years (range, 43 to 74) and median follow-up of 49 months. Seventy-six percent had Stage IIIA disease. Chemotherapy consisted of paclitaxel at 175 mg/m2 over 3 hours followed by carboplatin at AUC of 5 over 1 hour. Thoracic radiotherapy was given concurrently with the second and third cycles of chemotherapy. All patients received 50 Gray in 25 fractions over 5 weeks.
RESULTS:
The main toxicities were grade 3/4 neutropenia (30%), grade 3 infection (15 %) and grade 3 oesophagitis (9%). Twenty-five patients (76%) underwent surgery. Of the 8 who did not undergo surgery, 1 was deemed medically unfit after induction chemoradiotherapy and 4 had progressive disease; 3 declined surgery. Nineteen patients (58 %) had lobectomy and 6 had pneumonectomy. The median overall survival was 29.9 months and 12 patients are still in remission.
CONCLUSION:
The use of the triplemodality approach is feasible, with an acceptable tolerability and resectability rate in this group of patients
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Statistics and Epidemiology Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Annals of the Academy of Medicine Singapore | ||||
Publisher: | Academy of Medicine Singapore | ||||
ISSN: | 0304-4602 | ||||
Official Date: | 2008 | ||||
Dates: |
|
||||
Volume: | 37 | ||||
Number: | 5 | ||||
Page Range: | pp. 377-382 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Reuse Statement (publisher, data, author rights): | Cited By :7 Export Date: 5 March 2015 | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |